Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.
Shandong Boan Biotechnology Co., Ltd. has received U.S. FDA approval to initiate clinical trials for BA5101, a proposed biosimilar to the diabetes medication Trulicity, marking a significant milestone as the first of its kind developed by a Chinese company in the U.S. The company aims to address the substantial global diabetic market, leveraging dulaglutide’s benefits in glycemic control, safety, and cardiovascular protection. With the drug already under review in China and plans for U.S. and European marketing applications, Shandong Boan Biotechnology foresees a promising market opportunity for BA5101.
For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.
